Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05059106
Other study ID # FUES02
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date June 1, 2021
Est. completion date October 30, 2022

Study information

Verified date September 2021
Source Federal University of Espirito Santo
Contact Valéria Valim, PhD
Phone +5527999874665
Email val.valim@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is clinical trial (intervention study with external comparison group) to test vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years from Viana city - Espírito Santo (ES)/Brazil, on the incidence of new cases over 12 months following treatment, compared to an external group from same state and adjusted for socio-demographic and epidemiological variables.


Description:

This study is clinical trial (intervention study with external comparison group) to test vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years from Viana city - Espírito Santo (ES)/Brazil, on the incidence of new cases over 12 months following treatment, compared to an external group from same state and adjusted for socio-demographic and epidemiological variables. Cellular and humoral immunity will be studied in a representative sub-sample compared to an external reference group (cohort of health workers) vaccinated with standard dose. The outcomes will be evaluated at 28 days after the second dose and follow-up after 6 months and 12 months. The main outcome will be to decrease in 60% the incidence of new cases over 6 months after receiving the vaccine. The clinical epidemiological variables will be obtained from e-SUS VS, e-SUS notifica and datasus: number of cases, number of deaths with specific ICD for covid-19, number of hospital admissions for covid-19; number of ICU admissions for the treatment of SARS, total number of tests (RT-PCR) performed and positive. The cellular and humoral immune response will be assessed by viral neutralization assay (neutralizing antibody test), serological assay by chemiluminescence, determination of specific IgM and IgG profiles, measurement of systemic soluble factors (chemokines, cytokines and growth factors), stimulation antigen-specific peripheral blood mononuclear cells in vitro and investigation of memory T and B lymphocytes and intracytoplasmic cytokines. It is estimated to include 29,637 people in the study, to reach 85% vaccination cover of individuals aged 18-49 years. The subsample size immunogenicity test is 600 individuals from the eligible population, estimating losses of 15% and study power of 90%, alpha error of 1%. The hypothesis of the study is that the reduction in the incidence of covid-19 and the cellular and humoral immune response achieved with a half dose will be similar to the reduction expected with the standard dose.


Recruitment information / eligibility

Status Recruiting
Enrollment 29637
Est. completion date October 30, 2022
Est. primary completion date June 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria: - residents of Viana, Espírito Santo, aged between 18 and 49 years Exclusion Criteria: - Pregnant women; - History of severe allergic reaction (anaphylaxis) to any previously administered vaccine; - Having received another vaccine in the last 14 days; - Belonging to a priority risk group for vaccination, as per the PNI recommendations; - Have fever or flu-like symptoms; - Have previously received any vaccine for covid-19 at any time; - Recent diagnosis of covid-19 with onset of symptoms 28 days before vaccination; - Disorders of coagulation and use of anticoagulants.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Half dose of ChAdOx1 nCoV-19 (AZD1222)
Vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years, from non-priority groups, from Viana city - Espírito Santo (ES)/Brazil.
Standard dose of ChAdOx1 nCoV-19 (AZD1222)
Vaccination with standad dose of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, in external cohort of health workers aged 18 to 49 years.

Locations

Country Name City State
Brazil Federal University of Espirito Santo Vitória Espirito Santo

Sponsors (5)

Lead Sponsor Collaborator
Federal University of Espirito Santo Escola Nacional de Saúde Pública Sérgio Arouca/Fiocruz, Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória, Instituto René Rachou/Fiocruz, Programa de Computação Científica/Fiocruz

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Other Adverse events All adverse events will be followed up to establish severity and causal correlation. There will be surveillance of deaths and will be reported to the ethics committee. 14 months
Primary Incidence of new cases Incidence of new cases over 12 months following treatment 12 months
Secondary Number of deaths Number of deaths with specific ICD for covid-19 12 months
Secondary number of hospital admissions number of hospital admissions for covid-19 12 months
Secondary number of intensive care unit (ICU) admissions number of intensive care unit (ICU) admissions for the treatment of SARS 12 months
Secondary number of tests (RT-PCR) number of tests (RT-PCR) performed and positive 12 months
Secondary Viral Neutralization Assay Neutralizing antibody titers will be expressed by the ability of antibodies to neutralize up to 50% the number of plaques (PRNT50). Title > 1:50 will be considered positive. 4 and 8 months
Secondary serological assay Serological test by chemiluminescence. Results are expressed in U/mL and data interpretation will be done as follows: <0.8 U/mL = non-reactive sample; =0.8 U/mL = reactive sample. 8 and 10 months
Secondary IgM Determination of specific IgM profile. Results will be expressed in fluorescence intensity or pg/ml. 8 and 10 months
Secondary IgG Determination of specific IgG profile. Results will be expressed in fluorescence intensity or pg/ml. 8 and 10 months
Secondary systemic soluble factors Dosage of soluble systemic factors (chemokines, cytokines and growth factors). Results will be expressed in pg/ml. 8 and 10 months
Secondary Antigen-specific stimulation of peripheral blood mononuclear cells Antigen-specific stimulation of peripheral blood mononuclear cells in vitro. The results will be expressed in percentage positive frequency for a specific cell phenotype. 10 and 12 months
Secondary Lymphocyte investigation Investigation of memory T and B lymphocytes. The results will be expressed in percentage positive frequency for a specific cell phenotype. 10 and 12 months
Secondary Cytokine investigation Investigation of intracytoplasmic cytokines. The results will be expressed in percentage positive frequency for a specific cell phenotype. 10 and 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT05584202 - Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants Phase 2
Completed NCT04579549 - Repeat Testing for SARS-CoV-2 N/A
Active, not recruiting NCT05547243 - A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China N/A
Recruiting NCT04747574 - Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection Phase 1
Recruiting NCT04613310 - PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19) N/A
Completed NCT04515147 - A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 Phase 2
Terminated NCT04447404 - DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury Phase 2
Withdrawn NCT04388709 - Interferon Lambda Therapy for COVID-19 Phase 2
Active, not recruiting NCT05550142 - A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China N/A
Completed NCT04620798 - Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students N/A
Active, not recruiting NCT05547256 - A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China N/A
Completed NCT04452604 - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed NCT04561102 - Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
Completed NCT05366322 - A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Terminated NCT04958304 - Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
Completed NCT04690413 - NOWDx Test for the Detection of Antibodies to COVID-19 N/A